




Driving Biopharmaceutical Advancements of Plant-Derived Products

Avicanna is a commercial stage, diversified and vertically-integrated Canadian biopharmaceutical company focused on the research, development and commercialization of plant-derived products for global consumer, medical, and pharmaceutical market segments.



Ticker (Exchange)

AVCN (TSX)
AVCNF (OTCQX)
ONN (Frankfurt)

Stock Price (CAD)

\$0.34 CAD

Market Cap

\$20M CAD

Outstanding Shares

\$59M

Numbers rounded up and as of market close on July 28th.

Investment Highlights

- **De-risked investment** - commercial stage, with key regulatory approvals and milestones achieved, with several product lines
- **Diversified** - scalable and high margin revenue streams
- **Experienced management** - proven track record since 2016
- **Intellectual property powerhouse** - industry leading scientific platform
- **Disruptive** - pharmaceutical development approach to cannabinoid-based products
- **World-class partnerships** - clinical and commercial relationships in Canada and LATAM
- **Vertical integration** - low-cost and sustainable supply chain

Product Line & Brand	Canada - Medical	Canada - Adult Use	USA	Colombia	UK	Ecuador	Brazil	Chile	Peru	Portugal	Germany
RHO Phyto / Magisterial Medical	✓	✓		✓	2022						
Future Pharmaceutical Pipeline	*2024		*TBD	**2022		**2022	***2022				
Aureus API			✓	✓	✓	2022	✓	✓	✓	✓	✓
re+PLAY	✓	✓	✓								
Viola	✓	✓									
Pura H&W/Earth Dermocosmetics	✓	✓	✓	✓	2022	✓					✓

Advanced Product Lines

- **Pura H&W™ CBD-Derma Cosmetics | Commercial**
An innovative, clinically tested line of CBD consumer dermocosmetic products*
- **RHO Phyto™ Medical Cannabis | Commercial**
An advanced line of medical cannabis products in various deliveries and ratios of CBD and THC
- **Pharmaceuticals Pipeline**
Various indication specific cannabinoid-bases Pharmaceutical product in clinical development and registration stage
- **Cannabinoid API | Commercial**
An advanced line of medical cannabis products in various deliveries and ratios of CBD and THC

*Expected to be marketed as Pura Earth in Canada. Pura Earth products in Colombia are being rebranded to Pura H&W





Financial Highlights

	Q1 2021	Q2 2021	Q3 2021	Q4 2021	(Projected) 2022
Revenue	\$279,516	\$810,299	\$1,007,033	\$1,300,000	\$6,000,000
Units Delivered Globally	8,855	16,767	27,041	70,000*	250,000*

As an Established Leader in Cannabinoid Research and Development

R&D headquarters at JLABS @ Toronto, Johnson & Johnson Innovation Centre in the MaRS Discovery District. World-class research and clinical collaborations with leading Canadian academic and medical institutions. In addition to a burgeoning pharmaceutical pipeline, Avicanna's team of experts have developed and commercialized several industry leading product lines.



10+ Scientists



9 Pending Patents



30+ Proprietary Commercial Products



7 Canadian Government Research Grants Awarded Since 2020



4 Health Canada Cannabis Research Licenses to Avicanna or Institutional Collaborators

Strategic Partnership with:



The largest pharmacy chain in Canada for commercialization of RHO Phyto nation wide.



RHO Phyto™: Medical Cannabis - CBD, CBG and THC

- Complete, consistent, and scientifically advanced medical cannabis formulary.
- First medical cannabis brand to be available for dispensing in Canadian major hospitals.
- Currently commercial:
 - 21 SKUs in Canada in partnership with Medical Cannabis by Shoppers.
 - Across adult use channels in Ontario, Alberta, Saskatchewan, New Brunswick and Manitoba.
 - In Colombia under a magisterial prescription model.



Advanced Drug Delivery Systems
Avicanna's Intellectual property



Pre-Clinical Studies
Including in vitro, in vivo and stability studies



Accurate Dosing
GMP manufactured with consistent and accurate dosing



Designed for Patients
Easy to use, discrete and with pleasant taste

Executive Management Team

Aras Azadian
CEO, Director, and Co-Founder

Stephen Kim
Chief Legal Officer & General Counsel

Phillip Cardella
Chief Financial Officer

Lucas Nosiglia
CAO and President of LATAM

Ivana Maric
EVP Marketing

Dr. Frantz Le Devedec
EVP Research & Product Development

Investor Contact
ir@avicanna.com

Company Contact

Avicanna Inc.
480 University Ave, Suite 1502
Toronto, ON M5G 1V2 Canada
info@avicanna.com
www.Avicanna.com

Strategic Partnership with Al Harrington



Endorsed by the NBA Player's Association

Trunerox™ 10% CBD

Pharmaceutical drug preparation under GMP standards with completed technical dossier, using Avicanna's proprietary formulation and vertical integration to deliver an accessible pharmaceutical CBD product. Expected marketing authorization during 2022 in Colombia, Ecuador, Argentina, Mexico and Brazil.



*As a part of guidance provided by the company on February 2nd 2022